GLP-1 medications like Ozempic®, Wegovy®, and Mounjaro® have quickly become some of the most talked-about treatments for weight loss and metabolic health. But while the physical transformations are often celebrated, a new concern is quietly emerging — one that’s showing up in the skin.
If you’ve started to notice your skin looking thinner, looser, or more crepey after starting a GLP-1, you’re not alone. A growing number of individuals on these medications are reporting unexpected changes in skin texture and resilience. This emerging phenomenon has a name: GLP Face™.
But what exactly is happening beneath the surface? And why haven’t your skincare products caught up?
What Is GLP Face™? And How Is It Different From Normal Aging?
GLP Face™ is a term Dr. Few coined after observing a pattern of distinct skin changes in patients using GLP-1 drugs. Unlike the facial volume loss often seen with traditional weight loss, GLP Face™ is marked by:
- Thinner, less elastic skin
- Increased crepiness and surface roughness
- A loss of resilience, especially in the lower face, neck, and around the eyes
What’s causing these changes? Surprisingly, it's not just weight loss.
While shedding pounds can reduce subcutaneous fat and affect facial contours, our team’s research and my clinical observations suggest GLP-1 medications may be directly altering skin biology.
How GLP-1 Medications Impact Skin Function
Your skin isn’t just a passive outer layer. It’s a metabolically active organ that relies on steady cell turnover, robust collagen production, and a strong barrier to stay healthy and youthful.
GLP-1 receptor agonists are known to impact metabolism, digestion, and glucose regulation. But medical literature evidence suggests these same pathways may interfere with key skin functions by:
-
Slowing fibroblast activity, reducing the production of structural proteins like collagen and elastin
-
Decreasing cell turnover, leading to dullness and slower skin renewal
-
Compromising the skin barrier, increasing water loss and sensitivity to environmental damage
The result? A condition we now refer to as GLP Skin™ — skin that appears prematurely aged, stressed, and depleted.
Why Standard Skincare Isn’t Enough for GLP Skin™
Most skincare targeting the visible signs of aging is formulated to address chronological aging — the gradual collagen loss and oxidative stress that occur over decades. But GLP-induced skin changes can happen rapidly, often within a few months, and involve an entirely different biological mechanism.
This disconnect leaves many GLP-1 users frustrated: the products that once worked for them no longer deliver results, or worse, they seem to fall short altogether.
That’s exactly why Dr. Few developed DermaReverse™: the first topical solution formulated and clinically tested with a peer-reviewed and published study specifically for GLP-1 users.
DermaReverse™: Skincare Made for GLP Face™
Backed by peer-reviewed clinical research, DermaReverse™ is designed to counteract the visible and biological signs of GLP-1-induced skin aging. Unlike generic moisturizers or anti-aging serums, DermaReverse™ was engineered to:
-
Support collagen production by supporting fibroblast activity
-
Help strengthen the skin barrier and lock in hydration
-
Improve skin texture with ingredients that target structural integrity
-
Accelerate skin renewal, helping restore vibrancy and tone
In clinical testing, DermaReverse™ showed significant improvements in skin firmness, elasticity, hydration, and overall texture — especially in GLP-1 users experiencing symptoms of GLP Face™.
You’re Not Imagining It. But You’re Also Not Stuck With It
If your skin has changed since starting a GLP-1, there’s a reason. And now, there’s a solution.
DermaReverse™ was born out of the real clinical need Dr. Few identified in his surgical practice. It’s not just another anti-aging serum. It’s a science-backed response to a modern skincare challenge no one else was addressing.
Ready to take your skin back?
Explore DermaReverse™ at Dr. Few Skincare and see how it’s redefining what skincare can do for GLP-1 users.
